Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Yabing Guo, Masatoshi Kudo et al.|The Lancet|2023Cited by 514
Improved survival with regular surveillance imaging in patients with primary sclerosing cholangitisNatassia Tan, Ammar Majeed, Natalie Ngu et al.|Journal of Hepatology|2023Cited by 0